In future, patients should have access to innovative medicines on the day the product is authorised by Swissmedic («Day 0»).
Accounting for 46% of all exports, the EU was the Swiss pharmaceutical industry's biggest trading partner in 2019.
Pharmacological and technological innovations will bring about a fundamental change in the way medicines are developed and used, enabling new approaches to be adopted in research.
People in Switzerland benefit from access to high-quality healthcare provision. However, there is still a need for action and improvement in various areas.
show more articles
Interpharma, the association of Switzerland’s research-based pharmaceutical industry, was founded in Basel in 1933.
Interpharma informs the public about issues that are important to the research-based pharmaceutical industry in Switzerland, including the pharma market in Switzerland, healthcare and biomedical research.
Information on our key figures and activities in the financial year 2020
More about the tasks and overriding aims of Interpharma
Latest information and media contacts for media representatives